Current Corporate Collaborators
|Genentech (Erivedge®, vismodegib)||Hedgehog Pathway Inhibitor||Basal cell carcinoma, cancers|
|Debiopharm SA (Debio 0932)||Debio 0932 (Hsp90 inhibitor; formerly CUDC-305)||Cancer|
Curis is developing targeted small molecule drug candidates for cancer indications where there are substantial unmet therapeutic needs.
The Hedgehog pathway inhibitor program in collaboration with Genentech is our most advanced program. Curis’ collaborator Genentech (Roche) is commercializing Hedgehog pathway inhibitor Erivedge® (vismodegib) in the U.S. for advanced basal cell carcinoma. Roche continues to seek approvals for Erivedge in several different territories in this lead indication and is also testing Erivedge in less severe forms of BCC. Several additional clinical studies are ongoing under collaborations between Genentech and the National Cancer Institute and independent study investigators.
Our second development candidate under collaboration is Debio 0932 (formerly CUDC-305), an HSP90 inhibitor that we licensed to Debiopharm Group in August 2009 and that is currently the subject of Phase I/II clinical testing.